CoChat

Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers

Published version of a preprint

The DOI matches its Crossref record; 59 of the 61 references it cites were found in a registry or an index.

Abstract

KRAS, an oncogene mutated in nearly one third of human cancers, remains a pharmacologic challenge for direct inhibition except for recent advances in selective inhibitors targeting the G12C variant. Here, we report that selective inhibition of the protein tyrosine phosphatase, SHP2, can impair the proliferation of KRAS-mutant cancer cells in vitro and in vivo using cell line xenografts and primary human tumors. In vitro, sensitivity of KRAS-mutant cells toward the allosteric SHP2 inhibitor, SHP099, is not apparent when cells are grown on plastic in 2D monolayer, but is revealed when cells are grown as 3D multicellular spheroids. This antitumor activity is also observed in vivo in mouse models. Interrogation of the MAPK pathway in SHP099-treated KRAS-mutant cancer models demonstrated similar modulation of p-ERK and DUSP6 transcripts in 2D, 3D, and in vivo, suggesting a MAPK pathway–dependent mechanism and possible non-MAPK pathway–dependent mechanisms in tumor cells or tumor microenvironment for the in vivo efficacy. For the KRASG12C MIAPaCa-2 model, we demonstrate that the efficacy is cancer cell intrinsic as there is minimal antiangiogenic activity by SHP099, and the effects of SHP099 is recapitulated by genetic depletion of SHP2 in cancer cells. Furthermore, we demonstrate that SHP099 efficacy in KRAS-mutant models can be recapitulated with RTK inhibitors, suggesting RTK activity is responsible for the SHP2 activation. Taken together, these data reveal that many KRAS-mutant cancers depend on upstream signaling from RTK and SHP2, and provide a new therapeutic framework for treating KRAS-mutant cancers with SHP2 inhibitors.

Overview

Integrity signals

Registry

Crossref · 10.1158/1535-7163.mct-19-0170

Cites

59 of 59 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 59 references

Research works printed but not linked: 1

  1. Riedl, 2017, Comparison of cancer cells in 2D vs 3D culture reveals differences in AKT-mTOR-S6K signaling and drug responses, J Cell Sci, 130, 203

Cited by

See all 58

Metadata

Authors
Hao, H.-X., Wang, H., Liu, C., Kovats, S., Velazquez, R., Lu, H., Pant, B., Shirley, M., Meyer, M. J., Pu, M., Lim, J., Fleming, M., Alexander, L., Farsidjani, A., LaMarche, M. J., Moody, S., Silver, S. J., Caponigro, G., Stuart, D. D., Abrams, T. J., Hammerman, P. S., Williams, J., Engelman, J. A., Goldoni, S., & Mohseni, M.
Affiliations
  • 1Disease Area Oncology, Novartis Institute of Biomedical Research, Cambridge, Massachusetts.
  • 2Exploratory Immuno-Oncology, Novartis Institute of Biomedical Research, Cambridge, Massachusetts.
  • 3Global Discovery Chemistry, Novartis Institute of Biomedical Research, Cambridge, Massachusetts.
Venue
Molecular Cancer Therapeutics
Published
2019-12-01
Volume
18
Issue
12
Pages
2368-2380
ISSN
  • 1535-7163 (ISSN-L)
  • 1538-8514
OpenAlex
W2969870430
Cited by
53
References
61
Citations by year
2026: 4 · 2025: 8 · 2024: 9 · 2023: 7 · 2022: 9 · 2021: 7 · 2020: 9
FWCI
2.15
Type
journal article
Language
en
Open access
closed
Locations
  • Molecular Cancer Therapeutics (publishedVersion)
  • PubMed (publishedVersion)
  • The Novartis Repository (Novartis) (submittedVersion)
Funders
Novartis
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
Keywords
KRAS-mutant cancer, SHP2, SHP099, protein tyrosine phosphatase inhibition, receptor tyrosine kinase signaling, MAPK signaling, DUSP6, ERK1/2 phosphorylation, multicellular spheroids, tumor microenvironment, KRAS G12C, MIA PaCa-2 cells, antiangiogenic activity
MeSH terms
Animals, Disease Models, Animal, Female, Humans, Neoplasms, Tachykinins, Signal Transduction, Proto-Oncogene Proteins p21(ras), Xenograft Model Antitumor Assays, Cell Line, Tumor, Mice, Protein Tyrosine Phosphatase, Non-Receptor Type 11

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers. https://app.cochat.ai/papers/10.1158/1535-7163.mct-19-0170
The paper
Hao, H.-X., Wang, H., Liu, C., Kovats, S., Velazquez, R., Lu, H., Pant, B., Shirley, M., Meyer, M. J., Pu, M., Lim, J., Fleming, M., Alexander, L., Farsidjani, A., LaMarche, M. J., Moody, S., Silver, S. J., Caponigro, G., Stuart, D. D., . . . Mohseni, M. (2019). Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-19-0170

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.